hVIVO PLC (AIM:HVO) CEO Yamin 'Mo' Khan joined Steve Darling from Proactive to share details of a landmark achievement for the company. hLAB, the Group’s standalone virology and immunology laboratory service provider, has signed its largest contract to date—a £2.7 million deal with a US-based biotechnology client. This agreement brings the total project value to £3.2 million and further solidifies hLAB’s position as an industry leader in virology and clinical trial support.
With over 20 years of expertise in testing for quarantine and contracted studies, hLAB will serve as the sole virology laboratory for an international, multi-site Phase 2 field study. The study, involving 5,000 subjects, focuses on evaluating a US biotechnology client’s influenza drug candidate. Work is set to begin immediately, with hLAB providing critical virology and immunology lab services throughout the trial’s duration.
“This milestone contract represents a significant validation of hVIVO’s expertise and capabilities,” Khan stated. “It is the largest standalone laboratory services agreement in the company’s history and marks a pivotal step in expanding our footprint in the virology and immunology space.”
The majority of the revenue from this contract is anticipated in 2025, with the remainder recognised in 2026. This deal not only reinforces hVIVO’s reputation for excellence in clinical trial support but also signals continued growth opportunities for its standalone laboratory services.
With this contract, hVIVO is poised to make a meaningful contribution to the development of cutting-edge treatments for influenza, demonstrating its unwavering commitment to advancing global health through innovation in virology and immunology.
#proactiveinvestors #hvivo #aim #hvo #mokahn #ClinicalTrials #InfluenzaResearch #Virology #Immunology #hLAB #CanaryWharf #BiotechNews #DrugDevelopment
